| Not Yet Recruiting | Nemtabrutinib, Bortezomib, and Rituximab for WM NCT07464210 | Seoul National University Hospital | Phase 2 |
| Recruiting | Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or NCT07387471 | AbbVie | Phase 2 |
| Not Yet Recruiting | Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously NCT06547866 | French Innovative Leukemia Organisation | Phase 2 |
| Recruiting | A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lympho NCT07231952 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | Combating Cancer-Related Fatigue: A Personalized Supportive Care Program NCT06860880 | UNC Lineberger Comprehensive Cancer Center | N/A |
| Recruiting | Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia NCT05099471 | Christian Buske | Phase 2 |
| Recruiting | Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM NCT06561347 | Massachusetts General Hospital | Phase 2 |
| Recruiting | Epcoritamab in Previously Treated WM NCT06510491 | Gottfried von Keudell, MD PhD | Phase 2 |
| Recruiting | SynKIR-310 for Relapsed/Refractory B-NHL NCT06544265 | Verismo Therapeutics | Phase 1 |
| Recruiting | AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas NCT06340737 | Stanford University | Phase 1 |
| Recruiting | Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Mali NCT06151730 | Mayo Clinic | — |
| Active Not Recruiting | A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination Wit NCT05952037 | BeOne Medicines | Phase 2 |
| Recruiting | AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma NCT05602363 | Carna Biosciences, Inc. | Phase 1 |
| Recruiting | Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia NCT05734495 | Dana-Farber Cancer Institute | Phase 2 |
| Recruiting | Study of SGR-1505 in Mature B-Cell Neoplasms NCT05544019 | Schrödinger, Inc. | Phase 1 |
| Recruiting | Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macrog NCT05640102 | BeiGene | — |
| Recruiting | Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM NCT05914662 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Completed | Optical Coherence Tomography (OCT) and OCT Angiography(OCTA) Deep Learning in Waldenström's Macroglobulinemia NCT06084650 | Federico II University | — |
| Recruiting | Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström NCT04893564 | Centre Hospitalier Universitaire, Amiens | N/A |
| Recruiting | Loncastuximab Tesirine in WM NCT05190705 | Shayna Sarosiek, MD | Phase 2 |
| Withdrawn | HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL NCT05176691 | Hutchmed | Phase 1 |
| Recruiting | Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Ritu NCT04840602 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy NCT05065554 | Shayna Sarosiek, MD | Phase 2 |
| Unknown | PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies NCT05003141 | Qilu Puget Sound Biotherapeutics (dba Sound Biologics) | Phase 1 |
| Recruiting | Spanish Registry of Patients With IgM Monoclonal Gammopathies NCT05093153 | Fundación Española de Hematología y Hemoterapía | — |
| Active Not Recruiting | Study of Oral LOXO-338 in Patients With Advanced Blood Cancers NCT05024045 | Eli Lilly and Company | Phase 1 |
| Not Yet Recruiting | Establishment of Genomic, Transcriptomic and Functional Characteristics of Tumor Cells in Hyperinflammatory He NCT04702932 | Assistance Publique - Hôpitaux de Paris | — |
| Active Not Recruiting | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell NCT05020678 | Nkarta, Inc. | Phase 1 |
| Active Not Recruiting | Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinem NCT04263480 | Christian Buske | Phase 2 |
| Recruiting | Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. NCT04775745 | Newave Pharmaceutical Inc | Phase 1 |
| Completed | APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulin NCT04260217 | Ascentage Pharma Group Inc. | Phase 1 |
| Recruiting | Clinical Study of the Hyperviscosity Syndrome in Waldenström Macroglobulinemia NCT04898647 | Centre Hospitalier Universitaire, Amiens | N/A |
| Completed | The Registry of Oncology Outcomes Associated With Testing and Treatment NCT04028479 | Taproot Health | — |
| Completed | Covid-19 Vaccine Responsiveness in MM and Waldenstrom NCT04830046 | Massachusetts General Hospital | — |
| Active Not Recruiting | Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia NCT04624906 | Sunnybrook Health Sciences Centre | Phase 2 |
| Completed | Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T NCT04488354 | Calibr, a division of Scripps Research | Phase 1 |
| Withdrawn | Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 201 NCT04665115 | Academic and Community Cancer Research United | Phase 2 |
| Active Not Recruiting | A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies NCT04072458 | Bio-Path Holdings, Inc. | Phase 1 |
| Completed | CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies NCT04450069 | Calibr, a division of Scripps Research | Phase 1 |
| Terminated | Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia NCT03679624 | Weill Medical College of Cornell University | Phase 2 |
| Active Not Recruiting | Ibrutinib + Venetoclax in Untreated WM NCT04273139 | Dana-Farber Cancer Institute | Phase 2 |
| Active Not Recruiting | 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers NCT04464200 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I) NCT04018248 | Boryung Pharmaceutical Co., Ltd | Phase 1 |
| Withdrawn | ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies NCT04043845 | Dana-Farber Cancer Institute | Phase 1 |
| Recruiting | Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for NCT04061512 | University College, London | Phase 2 / Phase 3 |
| Completed | A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobuli NCT04042376 | Janssen Research & Development, LLC | Phase 4 |
| Terminated | Dasatinib In Waldenström Macroglobulinemia NCT04115059 | Jorge J. Castillo, MD | Phase 1 |
| Completed | Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyr NCT04116437 | BeiGene | Phase 2 |
| Completed | A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobuline NCT04062448 | Janssen Pharmaceutical K.K. | Phase 2 |
| Active Not Recruiting | Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia NCT03620903 | Christian Buske | Phase 2 |
| Completed | Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macr NCT03630042 | University College, London | Phase 2 |
| Terminated | Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders NCT03601819 | University of Michigan Rogel Cancer Center | Phase 1 |
| Active Not Recruiting | Rifaximin in Patients With Monoclonal Gammopathy NCT03820817 | Emory University | Phase 1 |
| Completed | A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL NCT03740529 | Loxo Oncology, Inc. | Phase 1 / Phase 2 |
| Completed | A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001 NCT03833180 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 1 |
| Unknown | A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobuline NCT03679455 | Polish Myeloma Consortium | Phase 2 |
| Completed | Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström's Macroglobulinemia and in NCT03521596 | Fondazione Italiana Linfomi - ETS | — |
| Terminated | Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinem NCT03506373 | Mayo Clinic | Phase 2 |
| Terminated | Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymph NCT03269552 | University of Washington | Phase 2 |
| Terminated | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Pa NCT03333486 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin NCT03364231 | TG Therapeutics, Inc. | Phase 2 |
| Completed | 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation NCT03133221 | University of Maryland, Baltimore | Phase 2 |
| Active Not Recruiting | Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus H NCT03192397 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom NCT02952508 | Cellectar Biosciences, Inc. | Phase 2 |
| Active Not Recruiting | A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 5 NCT03162536 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Phase 1 / Phase 2 |
| Completed | Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell NCT02257242 | Brown University | Phase 1 |
| Terminated | Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers NCT03037645 | Sunesis Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia NCT02962401 | French Innovative Leukemia Organisation | Phase 2 |
| Unknown | Study of VTD in Waldenstrom's Macroglobulinemia NCT03335098 | Seoul National University Hospital | Phase 2 |
| Completed | Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG NCT02916979 | Dartmouth-Hitchcock Medical Center | Phase 1 |
| Active Not Recruiting | Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma NCT02339922 | University of Washington | Phase 2 |
| Completed | Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia NCT02677324 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) NCT02669017 | ADC Therapeutics S.A. | Phase 1 |
| Completed | Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic L NCT02332980 | Mayo Clinic | Phase 2 |
| Terminated | Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection NCT02109224 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | B-Cell Hematologic Malignancy Vaccination Registry NCT02298816 | Wake Forest University Health Sciences | — |
| Recruiting | Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Ou NCT02269592 | Dana-Farber Cancer Institute | — |
| Active Not Recruiting | Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma NCT01479842 | Kami Maddocks, MD | Phase 1 |
| Terminated | A Phase II Study of Doxycycline in Relapsed NHL NCT02086591 | University of Rochester | Phase 2 |
| Recruiting | A Long-term Extension Study of PCI-32765 (Ibrutinib) NCT01804686 | Janssen Research & Development, LLC | Phase 3 |
| Completed | A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531 NCT01813227 | Hackensack Meridian Health | Phase 2 |
| Completed | Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell NCT01527045 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia NCT01779167 | Weill Medical College of Cornell University | Phase 2 |
| Completed | Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-C NCT01567709 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem NCT01529827 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies NCT01523223 | Robert Lowsky | Phase 1 |
| Terminated | Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies NCT01416428 | Amgen | Phase 1 / Phase 2 |
| Completed | Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic NCT01351935 | Celgene | Phase 1 |
| Completed | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma NCT01326702 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma NCT01261247 | Mayo Clinic | Phase 2 |
| Completed | Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma NCT01075321 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies NCT01273766 | Wake Forest University Health Sciences | Phase 2 |
| Completed | Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patient NCT01251575 | Fred Hutchinson Cancer Center | Phase 2 |
| Active Not Recruiting | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic NCT01199562 | City of Hope Medical Center | — |
| Completed | Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers NCT01254578 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia NCT01118689 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Completed | Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated NCT01231412 | Fred Hutchinson Cancer Center | Phase 3 |
| Completed | Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia NCT01109069 | Pharmacyclics LLC. | Phase 2 |
| Completed | AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lympho NCT01129193 | Amir Mortazavi | Phase 1 |
| Terminated | Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin L NCT01116154 | City of Hope Medical Center | Phase 1 |
| Completed | Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin NCT01076543 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients NCT01008462 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma NCT01045928 | Case Comprehensive Cancer Center | Phase 1 |
| Completed | A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle C NCT00861510 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 |
| Completed | Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia NCT02302469 | University Hospital, Lille | Phase 1 / Phase 2 |
| Completed | Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by NCT00789776 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia NCT00777738 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Completed | Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surg NCT00608361 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Lo NCT00711828 | Mayo Clinic | Phase 2 |
| Completed | Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Ritux NCT00783367 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Recruiting | Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic NCT00923507 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Completed | Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma NCT00720135 | City of Hope Medical Center | Phase 1 |
| Completed | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01093586 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease i NCT00105001 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Ref NCT00438880 | Mayo Clinic | Phase 1 / Phase 2 |
| Terminated | Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia NCT00113802 | Gilead Sciences | Phase 2 |
| Completed | Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma NCT00244855 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms NCT00082784 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treatin NCT00075478 | Fred Hutchinson Cancer Center | Phase 3 |
| Completed | Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Trea NCT00072514 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Ce NCT00096161 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | DT PACE, Tandem Autologous Transplant, Maintenance Therapy for Waldenstrom's Macroglobulinemia Patients NCT00107614 | University of Arkansas | Phase 2 |
| Active Not Recruiting | Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologi NCT00039676 | National Cancer Institute (NCI) | — |
| Completed | Nonmyeloablative Allogeneic Transplant NCT01272817 | Scripps Health | N/A |
| Withdrawn | Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia NCT00003512 | Burzynski Research Institute | Phase 2 |
| Completed | Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia NCT00083707 | University of Arkansas | Phase 2 |
| Completed | High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patient NCT01177371 | Case Comprehensive Cancer Center | Phase 2 |
| Approved For Marketing | Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer NCT05172700 | Loxo Oncology, Inc. | — |